Josep M. Llovet

Research interests

Publications

• AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma

  Hepatology · 2023 · https://doi.org/10.1097/hep.0000000000000466

• Hepatocellular carcinoma

  Nature Reviews Disease Primers · 2021 · https://doi.org/10.1038/s41572-020-00240-3

• Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma

  Nature Reviews Gastroenterology & Hepatology · 2021 · https://doi.org/10.1038/s41575-020-00395-0

• Immunotherapies for hepatocellular carcinoma

  Nature Reviews Clinical Oncology · 2021 · https://doi.org/10.1038/s41571-021-00573-2

• Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

  Journal of Clinical Oncology · 2020 · https://doi.org/10.1200/jco.20.00808

• Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2019 · 10.1016/s1470-2045(18)30937-9

• Molecular therapies and precision medicine for hepatocellular carcinoma

  Nature Reviews Clinical Oncology · 2018 · 10.1038/s41571-018-0073-4

• EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

  Journal of Hepatology · 2018 · https://doi.org/10.1016/j.jhep.2018.03.019

• Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet · 2016 · 10.1016/s0140-6736(16)32453-9

• Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets

  Nature Genetics · 2015 · 10.1038/ng.3252

• Genetic Landscape and Biomarkers of Hepatocellular Carcinoma

  Gastroenterology · 2015 · 10.1053/j.gastro.2015.05.061

• Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)00198-9

• Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma

  Journal of Hepatology · 2014 · 10.1016/j.jhep.2014.01.021

• EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer

  Journal · 2012

• Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial

  Journal of Hepatology · 2012 · 10.1016/j.jhep.2012.06.014

• Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma

  Seminars in Liver Disease · 2010 · https://doi.org/10.1055/s-0030-1247132

• α-Fetoprotein, Des-γ Carboxyprothrombin, and Lectin-Bound α-Fetoprotein in Early Hepatocellular Carcinoma

  Gastroenterology · 2009 · 10.1053/j.gastro.2009.04.005

• Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis

  The Lancet Oncology · 2008 · 10.1016/s1470-2045(08)70284-5

• Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma

  JNCI Journal of the National Cancer Institute · 2008 · 10.1093/jnci/djn134

• Sorafenib in Advanced Hepatocellular Carcinoma

  New England Journal of Medicine · 2008 · https://doi.org/10.1056/nejmoa0708857

• Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

  Molecular Cancer Therapeutics · 2008 · 10.1158/1535-7163.mct-08-0013

• Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma

  New England Journal of Medicine · 2008 · 10.1056/nejmoa0804525

• Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

  Hepatology · 2003 · 10.1053/jhep.2003.50047

• Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

  The Lancet · 2002 · 10.1016/s0140-6736(02)08649-x

• Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference

  Journal of Hepatology · 2001 · https://doi.org/10.1016/s0168-8278(01)00130-1

• Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification

  Seminars in Liver Disease · 1999 · 10.1055/s-2007-1007122

• Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation

  Hepatology · 1999 · 10.1002/hep.510300629

Current projects

No projects listed.